Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Dermatology Reports
Erschienen in: Current Dermatology Reports 1/2017

27.01.2017 | Psoriasis (J Wu, Section Editor)

Update on Ustekinumab for Psoriasis

verfasst von: John K. Nia, Peter W. Hashim, Grace Kimmel, Ahmad Aleisa, Ariana C. Farahani, Mark G. Lebwohl

Erschienen in: Current Dermatology Reports | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review will highlight the latest data on ustekinumab, as well as provide anecdotal evidence and insight into unanswered questions regarding its safety and the populations’ best suited for its use.

Recent Findings

In numerous clinical trials, ustekinumab has been found to be safe and efficacious. Many targeted psoriasis medications affecting the same pathway have since been approved as treatments. Recent data supports the notion that ustekinumab does not increase risk of cardiovascular events, and in fact, may be protective against them.

Summary

Targeted biologic medications for psoriasis have given insight into the complex interactions of the immune system. With these medications, patients suffering from psoriasis can now achieve up to 100 % skin clearance. Ustekinumab (Stelara®; Janssen Biotech, Inc.), a fully human monoclonal antibody against the p40 subunit of interleukin (IL) 12 and IL 23, was approved in 2009 for the treatment of moderate-to-severe plaque psoriasis and has become a standard against which other biologics are tested. Future studies should be directed toward exploring the long-term safety of ustekinumab, as well as efficacy of ustekinumab beyond 5 years of therapy.
Literatur
1.
Lebwohl M. Biologics for psoriasis: a translational research success story. J Invest Dermatol. 2015;135(5):1205–7.CrossRefPubMed
2.
Bartlett BL, Tyring SK. Ustekinumab for chronic plaque psoriasis. Lancet. 2008;371(9625):1639–40.CrossRefPubMed
3.
Au SC, Madani A, Alhaddad M, Alkofide M, Gottlieb AB. Comparison of the efficacy of biologics versus conventional systemic therapies in the treatment of psoriasis at a comprehensive psoriasis care center. J Drugs Dermatol. 2013;12(8):861–6.PubMed
4.
Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo Jr BF, et al. Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(2):262–9.CrossRefPubMed
5.
Famenini S, Wu JJ. The efficacy of ustekinumab in psoriasis. J Drugs Dermatol. 2013;12(3):317–20.PubMed
6.
Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–45.CrossRefPubMedPubMedCentral
7.
8.
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–25.CrossRefPubMed
9.
Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2010;130(5):1373–83.CrossRefPubMed
10.
Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat Biotechnol. 2011;29(7):615–24.CrossRefPubMed
11.
Stelara [package insert]. Horsham, PA: Janssen Biotech, Inc; 2014.
12.
• Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol. 2013;27(12):1535–45. This study demonstrated the stable clinical response for patients receiving ustekinumab through 5 years CrossRef
13.
•• Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Brit J Dermatol. 2015;172(5):1371–83. This study showed that treatment with ustekinumab was safe and effective, it went further to show that more frequent dosing improved response and was well tolerated CrossRef
14.
• Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, Shear NH, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74(5):851–861.e4.This is another study examining the efficacy of ustekinumab, this time comparing it to commonly used TNF inhibitors. It should be noted, however, that this study was sponsored by Janssen Research and Development.
15.
Zweegers J, Groenewoud JM, van den Reek JM, Otero ME, van de Kerkhof PC, Driessen RJ, et al. Comparison of the one and 5-years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: Results from the prospective BioCAPTURE registry. Br J Dermatol. 2016.
16.
Debbaneh M, Millsop JW, Bhatia BK, Koo J, Liao W. Diet and psoriasis, part I: Impact of weight loss interventions. J Am Acad Dermatol. 2014;71(1):133–40.CrossRefPubMedPubMedCentral
17.
Lebwohl M, Yeilding N, Szapary P, Wang Y, Li S, Zhu Y, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63(4):571–9.CrossRefPubMed
18.
Jullien D. Anti-drug antibodies, auto-antibodies and biotherapy in psoriasis. Ann Dermatol Venereol. 2012;139(Suppl 2):S58–67.CrossRefPubMed
19.
Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Investig Dermatol. 2015;135(1):31–8.CrossRefPubMed
20.
Chiu H-Y, Chu TW, Cheng Y-P, Tsai T-F. The association between clinical response to ustekinumab and immunogenicity to ustekinumab and prior adalimumab. PLoS One. 2015;10(11):e0142930.CrossRefPubMedPubMedCentral
21.
•• Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–14. This pharmaceutical sponsored registry found no increase in malignancy, MACE, serious infection, or mortality with ustekinumab PubMed
22.
Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor β1 deficiency: medical and immunological implications. J Exp Med. 2003;197(4):527–35.CrossRefPubMedPubMedCentral
23.
Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa J-M, Vanaclocha F, et al. Infections in moderate-to-severe psoriasis patients treated with biological drugs compared to classic systemic drugs: Findings from the BIOBADADERM registry. Journal of Investigative Dermatology.
24.
Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Brit J Dermatol. 2012;167(5):1145–52.CrossRef
25.
Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Brit J Dermatol. 2014;171(4):884–90.CrossRef
26.
Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Brit J Dermatol. 2013;169(6):1295–303.CrossRef
27.
Tzellos T, Kyrgidis A, Trigoni A, Zouboulis CC. Association of anti-IL-12/23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events. J Eur Acad Dermatol Venereol. 2013;27(12):1586–7.CrossRefPubMed
28.
Bigby M. The use of anti-interleukin-12/23 agents and major adverse cardiovascular events. Arch Dermatol. 2012;148(6):753–4.CrossRefPubMed
29.
Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomised controlled trials. Brit J Dermatol. 2016:n/a-n/a.
30.
•• Hjuler K, Bøttcher M, Vestergaard C, Bøtker H, Iversen L, Kragballe K. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatology. 2016;152(10):1114–21. This study examined the effect of biologics on development of coronary artery disease. Investigators found treatment with biologic agents was associated with reduced coronary artery disease progression in patients with severe psoriasis CrossRefPubMed
31.
Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatolog Treat. 2013;24(3):179–87.CrossRefPubMed
32.
Bertelsen T, Kragballe K, Johansen C, Iversen L. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol. 2014;53(10):e464–e6.CrossRefPubMed
33.
Landells I, Marano C, Hsu MC, Li S, Zhu Y, Eichenfield LF, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603.CrossRefPubMed
34.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780–9.CrossRefPubMed
35.
Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990–9.CrossRefPubMedPubMedCentral
36.
Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, et al. Ustekinumab treatment and improvement of physical function and health-related quality of life in patients with psoriatic arthritis. Arthritis Care Res (Hoboken). 2016.
37.
Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50.CrossRefPubMed
38.
39.
Wu JJ, Guerin A, Gauthier G, Sundaram M. Healthcare resource utilization, healthcare costs, and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. J Dermatolog Treat. 2016:1–23.
40.
Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):877–84.CrossRefPubMed
41.
Hsu DY, Gniadecki R. Patient adherence to biologic agents in psoriasis. Dermatology. 2016;232(3):326–33.CrossRefPubMed
Metadaten
Titel
Update on Ustekinumab for Psoriasis
verfasst von
John K. Nia
Peter W. Hashim
Grace Kimmel
Ahmad Aleisa
Ariana C. Farahani
Mark G. Lebwohl
Publikationsdatum
27.01.2017
Verlag
Springer US
Erschienen in
Current Dermatology Reports / Ausgabe 1/2017
Elektronische ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-017-0167-8

Weitere Artikel der Ausgabe 1/2017

Current Dermatology Reports 1/2017 Zur Ausgabe

Cutaneous Drug Reactions (J Brieva, Section Editor)

Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo

Atopic Dermatitis (T Bieber, Section Editor)

Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma

Hospital-based Dermatology (D Kroshinsky, Section Editor)

Hair and Nail Manifestations of Systemic Disease

Hospital- based Dermatology (D Kroshinsky, Section Editor)

Contact Dermatitis in the Hospitalized Patient

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

12.04.2024 | Vitiligo | Nachrichten

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

12.04.2024 | Atopische Dermatitis | Nachrichten

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

09.04.2024 | DGP 2024 | Kongressbericht | Nachrichten

Chemotherapie mit Hindernissen
weitere anzeigen

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise